Project Details
Description
PROJECT SUMMARY
The overall objective of the Mayo Clinic Center for Cell Signaling in Gastroenterology (C-SiG) is to exploit
signaling pathways in gastrointestinal cells to improve the health of patients with digestive diseases. To do this,
C-SiG provides a robust infrastructure, thematic platforms, and career development opportunities to integrate
and amplify impactful investigation along the discovery-translation-application paradigm. Our Research Base
now consists of 68 scientists (15% growth) involving 18 departments and $23.7 million (direct costs,
2.5% growth) in digestive disease-related funding. Responding to members' evolving interests and scientific
advances, we've re-aligned members into three interconnected Mechanistic Research Themes (intracellular
signaling, cell-to-cell communication, and genetics/epigenetics), each intersecting with three Disease
Focus Groups (liver pathobiology, enteric neurosciences, inflammation/transformation), a matrix that
fosters both discovery and disease relevant investigation. Our ongoing CENTRAL HYPOTHESIS is that
advances in care of patients with digestive diseases requires a facilitative infrastructure supporting meaningful
interactions among multidisciplinary scientists investigating cellular mechanisms, pathways, and therapeutic
targets to enhance rapid translation of basic discoveries into clinical trials. Our OVERALL SPECIFIC AIMS are
to: i) Foster multidisciplinary research by expanding technical and collaborative capabilities of established
GI scientists and attracting investigators from other disciplines; ii) Identify and nurture new GI investigators
via a peer-reviewed Pilot and Feasibility (P/F) Program including career development workshops, curricula,
and structured mentorship (19/26, 73% of P/F recipients achieving federal funding); iii) Offer core-based
specialized equipment, technologies, methodologies, reagents, and expertise (Optical Microscopy, Clinical,
and Gene Editing and Epigenomics Cores), with continuous core menu updates, quality assurance and
assessments, and project management oversight in response to member feedback; iv) Support a robust
Enrichment Program; and v) Promote interactions between C-SiG with other NIDDK centers at Mayo (e.g.,
PKD Center) and existing DDRCCs, especially in the Midwest (i.e., Midwest DDRCC Alliance). Our global
efforts have resulted in 215 manuscripts, with 56% percent intra- and 44% inter-thematic publications
(70% involving two or more members). Importantly, we've made critical advances in understanding disease
pathogenesis relevant to signal transduction, cell-to-cell communication and genetics/epigenetics, thereby
identifying potential disease modifying targets.
Status | Active |
---|---|
Effective start/end date | 9/1/09 → 6/30/24 |
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases: $1,192,500.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.